Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 88, Issue 1, 2014, Pages 136-147

  Carvalho, Simone R ^a   Watts, Alan B ^a   Peters, Jay I ^b   Liu, Sha ^a,c   Hengsawas, Soraya ^a   Escotet Espinoza, Manuel S ^d   Williams Iii, Robert O ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SHANDONG UNIVERSITY   (China)

^d The State University of New Jersey   (United States)

Author keywords

Dry powder; Inhalation; Rapamycin; Thin film freezing Pharmacokinetics Particle engineering Formulation delivery

Indexed keywords

AEROSOL; ANTIINFECTIVE AGENT; POWDER; RAPAMYCIN;

AEROSOL; ANIMAL; AREA UNDER THE CURVE; CHEMISTRY; CRYSTALLIZATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; LUNG LAVAGE; NEBULIZER; PARTICLE SIZE; POWDER; RAT; SCANNING ELECTRON MICROSCOPY; SOLUBILITY; SPRAGUE DAWLEY RAT; TEMPERATURE; THERMOGRAVIMETRY; X RAY DIFFRACTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BRONCHOALVEOLAR LAVAGE FLUID; CRYSTALLIZATION; LUNG; MICROSCOPY, ELECTRON, SCANNING; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; POWDERS; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; SOLUBILITY; TEMPERATURE; THERMOGRAVIMETRY; X-RAY DIFFRACTION;

EID: 84934280348     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.05.008     Document Type: Article

References (51)

1. S. Sehgal Sirolimus: its discovery, biological properties, and mechanism of action Transplant. Proc. 35 2003 S7 S14 10.1016/S0041-1345(03)00211-2
2. P.N. Chhajed, M. Dickenmann, L. Bubendorf, M. Mayr, J. Steiger, and M. Tamm Patterns of pulmonary complications associated with sirolimus Respiration 73 2006 367 374
3. L.J. Stuckey, C.E. Bartos, H.A. McCullough, R.D. Florn, V.N. Lama, and J. Lin Use of sirolimus in lung transplantation: a single center experience J. Heart Lung Transplant. 32 2013 S89 10.1016/j.healun.2013.01.990
4. F.X. McCormack, Y. Inoue, J. Moss, L.G. Singer, C. Strange, and K. Nakata Efficacy and safety of sirolimus in lymphangioleiomyomatosis N. Engl. J. Med. 364 2011 1595 1606 10.1056/NEJMoa1100391
5. A.M. Taveira-DaSilva, O. Hathaway, M. Stylianou, and J. Moss Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus Ann. Intern. Med. 154 2011 797 805 W-292-293. doi: http://dx.doi.org/10.1059/0003-4819-154-12-201106210-00007
6. P. Simamora, J.M. Alvarez, and S.H. Yalkowsky Solubilization of rapamycin Int. J. Pharm. 213 2001 25 29 10.1016/S0378-5173(00)00617-7
7. A. MacDonald, J. Scarola, J.T. Burke, and J.J. Zimmerman Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus Clin. Ther. 22 Suppl. 2 2000 B101 B121 10.1016/S0149-2918(00)89027-X
8. D.J. Hauss Oral Lipid-Based Formulations: Enhancing the Bioavailability of Poorly Water-Soluble Drugs 2007 CRC Press
9. L.-J. Shen, and F.-L.L. Wu Nanomedicines in renal transplant rejection - focus on sirolimus Int. J. Nanomed. 2 2007 25 32 10.2147/nano.2007.2.1.25
10. R. Müller, and Junghanns Nanocrystal technology, drug delivery and clinical applications Int. J. Nanomed. 2008 295 10.2147/IJN.S595
11. B.D. Kahan, J.Y. Chang, and S.N. Sehgal Preclinical evaluation of a new potent immunosuppressive agent, rapamycin Transplantation 52 1991 185 191
12. S.-J. Hwang, Min-Soo Kim, Jeong-Soo Kim, Hee Jun Park, Won Kyung Cho, and Kwang-Ho Cha Enhanced bioavailability of sirolimus via preparation of solid dispersion nanoparticles using a supercritical antisolvent process Int. J. Nanomed. 2011 2997 10.2147/IJN.S26546
13. A.Y. Alemdar, D. Sadi, V.C. McAalister, and I. Mendez Liposomal formulations of tacrolimus and rapamycin increase graft survival and fiber outgrowth of dopaminergic grafts Cell Transplant. 13 2004 263 271 10.3727/000000004783983936
14. A.C. Preetham, and C.S. Satish Formulation of a poorly water-soluble drug sirolimus in solid dispersions to improve dissolution J. Dispers. Sci. Technol. 32 2011 778 783 10.1080/01932691.2010.488129
15. J.S. Patton, and P.R. Byron Inhaling medicines: delivering drugs to the body through the lungs Nat. Rev. Drug Discov. 6 2007 67 74 10.1038/nrd2153
16. W. Yang, K.P. Johnston, and R.O. Williams III Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats Eur. J. Pharm. Biopharm. 75 2010 33 41 10.1016/j.ejpb.2010.01.011
17. N.A. Beinborn, J. Du, N.P. Wiederhold, H.D.C. Smyth, R.O. Williams III, Dry powder insufflation of crystalline and amorphous voriconazole formulations produced by thin film freezing to mice, Eur. J. Pharm. Biopharm. (n.d.) 81 (2012) 600-608.
18. K.A. Overhoff, J.D. Engstrom, B. Chen, B.D. Scherzer, T.E. Milner, and K.P. Johnston Novel ultra-rapid freezing particle engineering process for enhancement of dissolution rates of poorly water-soluble drugs Eur. J. Pharm. Biopharm. 65 2007 57 67 10.1016/j.ejpb.2006.07.012
19. General Chapters <601> Aerosols, Nasal Sprays, Metered-dose Inhalers, and Dry Powder Inhaler, in: U.S. Pharmacop.; 35th-NF ed.; n.d.
20. D. Cattaneo, N. Perico, and F. Gaspari Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection J. Chromatogr. B 774 2002 187 194 10.1016/S1570-0232(02)00204-0
21. M. Ricciutelli, P. Di Martino, L. Barboni, and S. Martelli Evaluation of rapamycin chemical stability in volatile-organic solvents by HPLC J. Pharm. Biomed. Anal. 41 2006 1070 1074 10.1016/j.jpba.2006.02.009
22. P.J. Kuehl, T.L. Anderson, G. Candelaria, B. Gershman, K. Harlin, and J.Y. Hesterman Regional particle size dependent deposition of inhaled aerosols in rats and mice Inhal. Toxicol. 24 2012 27 35 10.3109/08958378.2011.632787
23. D.E. Harrison, R. Strong, Z.D. Sharp, J.F. Nelson, C.M. Astle, and K. Flurkey Rapamycin fed late in life extends lifespan in genetically heterogeneous mice Nature 460 2009 392 395 10.1038/nature08221
24. R.A. Miller, D.E. Harrison, C.M. Astle, J.A. Baur, A.R. Boyd, and R. de Cabo Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice J. Gerontol. A: Biol. Sci. Med. Sci. 66A 2011 191 201 10.1093/gerona/glq178
25. S. Majumder, A. Caccamo, D.X. Medina, A.D. Benavides, M.A. Javors, and E. Kraig Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1 ss and enhancing NMDA signaling Aging Cell 11 2012 326 335 10.1111/j.1474-9726.2011.00791.x
26. T.L. Rogers, A.C. Nelsen, J. Hu, J.N. Brown, M. Sarkari, and T.J. Young A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid Eur. J. Pharm. Biopharm. 54 2002 271 280 10.1016/S0939-6411(02)00063-2
27. A.B. Watts, Y.-B. Wang, K.P. Johnston, and R.O. Williams Respirable low-density microparticles formed in situ from aerosolized brittle matrices Pharm. Res. 30 2013 813 825 10.1007/s11095-012-0922-2
28. M.K. Haque, K. Kawai, and T. Suzuki Glass transition and enthalpy relaxation of amorphous lactose glass Carbohydr. Res. 341 2006 1884 1889 10.1016/j.carres.2006.04.040
29. H. Steckel, and N. Bolzen Alternative sugars as potential carriers for dry powder inhalations Int. J. Pharm. 270 2004 297 306
30. A. Baheti, L. Kumar, and A.K. Bansal Excipients used in lyophilization of small molecules J. Excip. Food Chem. 1 2010 41 54
31. FisherScientific, Material Safety Data Sheet: Acetonitrile [HPLC], 2009.
32. S. Garnier, S. Petit, and G. Coquerel Dehydration mechanism and crystallisation behaviour of lactose J. Therm. Anal. Calorim. 68 2002 489 502 10.1023/A:1016087702409
33. F. Monajjemzadeh, D. Hassanzadeh, H. Valizadeh, M.R. Siahi-Shadbad, J.S. Mojarrad, and T.A. Robertson Compatibility studies of acyclovir and lactose in physical mixtures and commercial tablets Eur. J. Pharm. Biopharm. 73 2009 404 413 10.1016/j.ejpb.2009.06.012
34. N. Rasenack, and B.W. Muller Micron-size drug particles: common and novel micronization techniques Pharm. Dev. Technol. 9 2004 1 13 10.1081/PDT-120027417
35. A. Saleki-Gerhardt, C. Ahlneck, and G. Zografi Assessment of disorder in crystalline solids Int. J. Pharm. 101 1994 237 247 10.1016/0378-5173(94)90219-4
36. O. of the Commissioner, Inspection Guides - Lyophilization of Parenterals (7/93) (n.d.).
37. H. Mohammed, D.L. Roberts, M. Copley, M. Hammond, S.C. Nichols, and J.P. Mitchell Effect of sampling volume on dry powder inhaler (DPI)-emitted aerosol aerodynamic particle size distributions (APSDs) measured by the next-generation pharmaceutical impactor (NGI) and the Andersen eight-stage cascade impactor (ACI) AAPS PharmSciTech 13 2012 875 882 10.1208/s12249-012-9797-0
38. T.C. Carvalho, J.I. Peters, and R.O. Williams III Influence of particle size on regional lung deposition - what evidence is there? Int. J. Pharm. 406 2011 1 10 10.1016/j.ijpharm.2010.12.040
39. J. Dijoseph, R. Sharma, and J. Chang The effect of rapamycin on kidney-function in the Sprague-Dawley rat Transplantation 53 1992 507 513 10.1097/00007890-199203000-00002
40. B.M. Meiser, J. Wang, and R.E. Morris Rapamycin: a new and highly active immunosuppressive macrolide with an efficacy superior to cyclosporine F. Melchers, E.D. Albert, H. Boehmer, M.P. Dierich, L. Pasquier, K. Eichmann, Prog. Immunol. 1989 Springer Berlin, Heidelberg 1195 1198
41. B. Hausen, K. Boeke, G.J. Berry, I.T. Segarra, U. Christians, and R.E. Morris Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant. 18 1999 150 159
42. K.L. Napoli, M.-E. Wang, S.M. Stepkowski, and B.D. Kahan Distribution of sirolimus in rat tissue Clin. Biochem. 30 1997 135 142 10.1016/S0009-9120(96)00157-9
43. W. Stahlhofen, R. Koebrich, G. Rudolf, and G. Scheuch Short-term and long-term clearance of particles from the upper human respiratory tract as function of particle size J. Aerosol Sci. 21 1990 S407 S410
44. J.A. Tolman, and R.O. Williams Advances in the pulmonary delivery of poorly water-soluble drugs: influence of solubilization on pharmacokinetic properties Drug Dev. Ind. Pharm. 36 2010 1 30 10.3109/03639040903092319
45. J.A. Yanez, M.L. Forrest, Y. Ohgami, G.S. Kwon, and N.M. Davies Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin Cancer Chemother. Pharmacol. 61 2008 133 144 10.1007/s00280-007-0458-z
46. John S. Patton, C. Simone Fishburn, and Jeffry G. Weers The lungs as a portal of entry for systemic drug delivery (thoracic) Am. Thorac. Soc. 1 2004 338 344 10.1513/pats.200409-049TA
47. J. Ferin Pulmonary retention and clearance of particles Toxicol. Lett. 72 1994 121 125 10.1016/0378-4274(94)90018-3
48. C. Lombry, D.A. Edwards, V. Preat, and R. Vanbever Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules Am. J. Physiol.-Lung Cell. Mol. Physiol. 286 2004 L1002 L1008 10.1152/ajplung.00260.2003
49. N.R. Labiris, and M.B. Dolovich Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications Br. J. Clin. Pharmacol. 56 2003 588 599 10.1046/j.1365-2125.2003.01892.x
50. D.E. Alonzo, G.G. Zhang, D. Zhou, Y. Gao, and L.S. Taylor Understanding the behavior of amorphous pharmaceutical systems during dissolution Pharm. Res. 27 2010 608 618
51. J.M. Vaughn, J.T. McConville, M.T. Crisp, K.P. Johnston, and R.O. Williams III Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies Drug Dev. Ind. Pharm. 32 2006 559 567 10.1080/03639040500529176